Bioelectrics Seminar
<p> <strong>Frank Reidy Research Center for Bioelectrics Seminar</strong></p> <p> </p> <p> <strong>“Hypoxia reversion and stable tumor vessel normalization following treatment with Inositol tris Pyrophosphate: A new anti-tumor therapy?”</strong></p> <p> </p> <p> <strong>Claude Nicolau, Ph.D.</strong></p> <p> Founder, NormOxys, Inc.</p> <p> Visiting Professor, Friedman School of Nutrition Science and Policy</p> <p> Tufts University</p> <p> Boston, MA</p> <p> </p> <p> <strong>Tuesday, February 25, 2014, 9-10AM</strong></p> <p> <strong>IRP2 First Floor Conference Room</strong></p> <p> <strong>4211 Monarch Way</strong></p> <p> <strong>All are invited</strong></p> <p> </p> <p> <strong>Â </strong><strong>Dr. Claude Nicolau</strong> is recognized as an international leader in cellular biophysics. His main area of work is the study of membrane involvement in pharmacological processes at the molecular Level, allosteric control of oxygen delivery by red blood cells and therapy of Alzheimer’s Disease. Dr. Nicolau and Dr. Lehn founded Alantos, Inc. which was acquired by Amgen for $300 million. Dr. Nicolau and Dr. Lehn were the cofounders of AC Immune, SA which has to date sold two worldwide exclusive licenses to Genentech for $755 million. Dr. Nicolau is a Member of the Scientific Board of AC Immune, SA. He reported <a href="http://www.ncbi.nlm.nih.gov/pubmed/8766704">the first gene transfer and expression in a live animal</a> and has developed the technique of <a href="http://www.ncbi.nlm.nih.gov/pubmed/2204427">Protein Electro Insertion</a> into cell plasma membranes. He has published 230 scientific papers and has been awarded 80 patents to-date.</p>
Posted By: Loree Heller
Date: Tue Feb 18 11:54:50 EST 2014